Amarantus BioScience Holdings, Inc.

OTCPK:AMBS Stock Report

Market Cap: US$630.0

Amarantus BioScience Holdings Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenure8.7yrs
Board average tenure10.6yrs

Recent management updates

No updates

Recent updates

No updates

CEO

Amarantus BioScience Holdings has no CEO, or we have no data on them.

Leadership Team

NamePositionTenureCompensationOwnership
John Commissiong
Chief Scientific Officer17.1yrsno datano data
Robert Harris
Compliance Officer & Directorno datano datano data
Aimee Boutcher
Director of Investor Relationsno datano datano data
Ravi Kiron
Senior Vice President of Business Development8.7yrsno datano data
Brian Harvey
Chief Regulatory Advisor & Member of Board of Advisors6.8yrsno datano data
Owen Garrick
Corporate Advisorno datano datano data

8.7yrs

Average Tenure

79yo

Average Age

Experienced Management: AMBS's management team is seasoned and experienced (8.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John Commissiong
Chief Scientific Officer17.1yrsno datano data
Robert Harris
Compliance Officer & Director14.2yrsno datano data
Brian Harvey
Chief Regulatory Advisor & Member of Board of Advisors8.9yrsno datano data
Owen Garrick
Corporate Advisorno datano datano data
Donald Huffman
Independent Director10.6yrsno datano data
Steven Spence
Director8yrsno datano data
Lawrence Schwartz
Member of Scientific Advisory Boardno datano datano data

10.6yrs

Average Tenure

78yo

Average Age

Experienced Board: AMBS's board of directors are seasoned and experienced ( 10.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 02:12
End of Day Share Price 2025/01/10 00:00
Earnings2019/06/30
Annual Earnings2018/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Amarantus BioScience Holdings, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pooya HemamiEdison Investment Research
Ajay TandonSeeThruEquity, LLC
Jason NapodanoZacks Investment Research Inc.